Previous 10 | Next 10 |
2023-11-02 14:19:05 ET Cellectar Biosciences, Inc. (CLRB) Q3 2023 Earnings Conference Call November 02, 2023, 08:30 ET Company Participants Monique Kosse - LifeSci Advisors James Caruso - CEO Chad Kolean - CFO Shane Lea - CCO Andrei Shustov - SVP, Medical...
Reports Preliminary Financial Results for Third Quarter 2023 and Provides a Corporate Update Conference Call scheduled for today at 8:30 am Eastern Time FLORHAM PARK, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical bio...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Cellectar Biosciences Inc. (CLRB) is expected to report $-0.44 for Q3 2023
2023-11-01 14:15:25 ET More on Cellectar Biosciences Seeking Alpha’s Quant Rating on Cellectar Biosciences Historical earnings data for Cellectar Biosciences Financial information for Cellectar Biosciences For further details see: Cellectar Bioscie...
2023-11-01 11:48:22 ET Major earnings expected before the bell on Thursday include: Barrick Gold ( GOLD ) Moderna ( MRNA ) Palantir Technologies ( PLTR ) Starbucks ( SBUX ) Shopify ( SHOP ) For further details see: Notable earnings before ...
Strategic collaboration to advance patient care and further define the U.S. treatment landscape First of several planned community-based cancer care network collaborations for Cellectar to facilitate future patient access and clinical success with iopofosine I 131 FLORHAM PARK, N....
FLORHAM PARK, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted drugs for the treatment of cancer, today announced that the company will repor...
William Yoon Appointed Vice President, Medical Affairs Aaditya Nanduri Appointed Vice President, Business Strategy and Analytics FLORHAM PARK, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focuse...
2023-10-05 16:56:44 ET More on Cellectar Biosciences Seeking Alpha’s Quant Rating on Cellectar Biosciences Historical earnings data for Cellectar Biosciences Financial information for Cellectar Biosciences For further details see: Cellectar Bioscie...
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40%...
FLORHAM PARK, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the majority of Tranche B warran...
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...